Adverse Events With Dabrafenib/Trametinib Combination in Melanoma
Jeffrey S. Weber, MD, PhD, deputy director of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the adverse events commonly associated with the combination of dabrafenib and trametinib in the adjuvant setting for patients with BRAF V600E– or V600K–positive stage III melanoma.
Jeffrey S. Weber, MD, PhD, deputy director of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the adverse events (AEs) commonly associated with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in the adjuvant setting for patients withBRAFV600E or V600K–positive stage III melanoma.
According to Weber, the AEs are very similar to those found with the combination in patients with metastatic disease. However, fatigue and fevers are the most difficult to deal with after receiving this combination. Weber says these 2 particular AEs have led to a number of discontinuations of the treatment as it can be debilitating to the patient.
